PCSK9 and familial hyperaldosteronism: Real-world evidence on alirocumab [128] and evolocumab, obtained from the RAMAN and HAUSER-OLE studies, suggests using PCSK9 inhibitors to achieve a reduction equal to or above 15%, translating into an absolute reduction of >60 mg/dL, for the treatment of pediatric FH [129].